Active, Not Recruiting

Trial ID CA043-001 | NCT03994601

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Sorry, this study is no longer accepting new participants, but is still ongoing.

You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.

Check Your Eligibility

About This Trial
Key Eligibility Criteria

Summary

Phase 1/Phase 2
18+

Age Range
Active, Not Recruiting

Overview

The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.

Key Eligibility Criteria

Inclusion Criteria: - Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies Exclusion Criteria: - Active, known or suspected autoimmune disease - Active malignancy requiring concurrent intervention - Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded Other protocol-defined inclusion/exclusion criteria apply

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Study Arms

Experimental: Arm A: BMS-986288 Monotherapy

ASSIGNED INTERVENTION

Drug: BMS-986288

Study Arms

Experimental: Arm B: BMS-986288 in combination with Nivolumab

ASSIGNED INTERVENTION

Drug: BMS-986288, Nivolumab

Study Arms

Experimental: Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib

ASSIGNED INTERVENTION

Drug: BMS-986288, Regorafenib, Nivolumab